Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.

Inclusion Criteria: * Adult hemodialysis patients ≥18 years of age. * Signed informed consent to participate in the study. * Stable on hemodialysis prescription for ≥3 months. * Able to sustain hemodialysis 3x/week for 3 to 4 hours. * Hemoglobin concentration \>9.5 g/dL. * Serum TSAT ≥20%. * Receiving hemodialysis via AV fistula or graft. * Able to receive hemodialysis for 4 hours at each session over the duration of the treatment periods. * Able to receive intermittent heparin administration for anticoagulation of the dialysis circuit. * Serum TIBC ≥ 150 µg/dL. Exclusion Criteria: * Active bleeding disorder (GI, skin, nasal…) * Receiving hemodialysis via catheter. * Receiving IV iron within 10 days of the first on-study hemodialysis treatment. * Receiving oral iron within 10 days of the first on-study hemodialysis treatment. * Any other condition, that in the opinion of the investigator would not allow completion of the 4 hemodialysis treatments in the study.